News

Real Matters Q3 Financial Performance: Trends and Insights

Real Matters Q3 Financial Performance: Trends and Insights

Real Matters Reports Impressive Q3 Financial Results

(All amounts are expressed in millions of U.S. dollars, excluding per share amounts, unless otherwise stated.)

TORONTO – Real Matters Inc. (TSX: REAL), a leader in providing network management services for the mortgage and insurance sectors, has announced its financial results for the third quarter, showcasing a robust performance.

The company saw its consolidated revenues rise by 22% sequentially in this quarter, achieving a total of $45.4 million. This increase aligns with a seasonal surge in U.S. appraisal mortgage market volumes and positive growth in all operational segments. Notably, Real Matters managed to convert a previous loss into an adjusted EBITDA of $0.3 million, a significant milestone from the prior quarter's loss of $1.9 million.

CEO Brian Lang stated that the company successfully brought in new clients across its three segments and performed exceptionally well on lender scorecards. Furthermore, post-quarter operations included onboarding a major lender in the U.S. Title sector, demonstrating the firm’s continuous growth trajectory.

Financial Highlights for Q3 2025

The financial highlights for the third quarter are as follows:

  • Revenue of $45.4 million, an 8% decrease year-over-year, primarily driven by lower U.S. Appraisal revenue.
  • Adjusted EBITDA of $0.3 million, compared to $1.7 million in Q3 of the previous year.
  • A net loss of $4.9 million, a sharp decline from a net income of $1.7 million year-over-year, attributed to a significant increase in net foreign exchange losses.
  • Launched four new clients, reinforcing the company's market presence.
  • U.S. Appraisal mortgage origination volumes decreased 16% year-over-year, attributed to declining purchase origination volumes.
  • U.S. Title mortgage origination volumes surged by 52% year-over-year, driven by market share expansion and increased refinance origination volumes.
  • Cash and cash equivalents stood at $43.8 million with no debt as of the quarter-end.

Operational Insights

Real Matters continued to expand its client acquisition strategy, launching new partnerships that broaden its service offerings. The company emphasizes the potential in the current mortgage landscape; approximately 12 million mortgages have interest rates above 6%, with about 8 million exceeding 6.5%. This presents a significant refinancing opportunity, positioning Real Matters strategically for future market fluctuations.

Despite facing some challenges, particularly in the U.S. Appraisal segment, the company's overall operational adjustments and market strategies have fortified its readiness to capture these opportunities.

Future Outlook and Market Strategy

The leadership team at Real Matters remains positive about the future. The company's strategy focuses on expanding market share and optimizing operations to scale rapidly when mortgage market volumes return to normal levels. This proactive approach positions them as a key player in both the mortgage and insurance sectors.

Real Matters is well-prepared and strategically positioned to take advantage of a market rebound, continuing to leverage its robust technology and established network of professionals.

Conference Call Announcement

A conference call is scheduled for 10:00 AM (ET) to discuss these results, hosted by CEO Brian Lang and CFO Rodrigo Pinto. Investors and analysts can expect insights into the company's performance, market trends, and strategy for upcoming quarters.

To participate, individuals are encouraged to pre-register online. Dial-in details will be sent via email upon registration.

Frequently Asked Questions

What were Real Matters' total revenues for Q3 2025?

The total revenues for Q3 2025 were $45.4 million.

What is the adjusted EBITDA reported by Real Matters for this quarter?

The company reported an adjusted EBITDA of $0.3 million for Q3 2025.

What factors contributed to Real Matters' net loss this quarter?

The net loss of $4.9 million was largely due to an increase in net foreign exchange losses.

How many new clients did Real Matters launch during this quarter?

Real Matters successfully launched four new clients this quarter.

How does Real Matters plan to approach the future market opportunities?

The company plans to expand its market share, optimize operations, and be prepared to scale as market volumes normalize.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
More News Articles